Tempus AI, Inc. (BCBA:TEM)
Argentina · Delayed Price · Currency is ARS | Market Cap | 12.30T +11.0% |
| Revenue (ttm) | 1.88T +69.8% |
| Net Income | -418.47B |
| EPS | -2,380.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279 |
| Open | 6,040.00 |
| Previous Close | 6,185.00 |
| Day's Range | 5,950.00 - 6,200.00 |
| 52-Week Range | 5,165.00 - 13,350.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Tempus AI announces publication of multi-center validation of software
Tempus AI (TEM) announced publication of a multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrilla...
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation ...
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrati...
Tempus AI Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Tempus integrates molecular and clinical data at scale, driving growth in diagnostics and data-driven AI applications. Rising sequencing prices and FDA approvals are boosting revenues, while partnerships and proprietary data position the company as a key player in pharma R&D and clinical trials.
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47...
Tempus AI launches open-source digital pathology consortium
Tempus AI (TEM), Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center announced the launch of a digital pathology IMS Open-Source Consortium. The consortium aims to bring together acade...
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Canc...
Tempus AI assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Tempus AI (TEM) with a Peer Perform rating and no price target The company’s data offering is “differentiated” versus peers but lacks clarity around its…
Tempus AI announced the upcoming clinical availability of xH
Tempus AI (TEM) announced the upcoming clinical availability of xH, a next-generation sequencing, NGS, test that uses a whole-genome sequencing, WGS, approach for the detection of actionable oncologic...
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next...
Short Report: Tempus AI short interest at record high
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs
Tempus AI (TEM) announced the launch of the PRECISION Challenge, an initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its model. The PRECISION Challenge will...
Tempus AI announces introduction of Tempus Preview
Tempus AI (TEM) announced the introduction of Tempus Preview. “Tempus Preview offers preliminary results in the critical window between when a diagnostic test is ordered and when final sequencing resu...
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its p...
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a nationa...
Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an applicati...
Tempus AI expects 25% top-line growth over next 3 years
In investor presentation slides, Tempus AI (TEM) stated: “We expect 25% top-line growth over the next 3 years supported by continued strength in Diagnostics and expanding scale in our Data…
Tempus AI reiterates FY26 revenue view of $1.59B-$1.6B, consensus $1.59B
Reiterates FY26 adjusted EBITDA view of roughly $65M. Guidance from investor day slides.
Tempus AI announces initial results from Multimodal Foundation Model efforts
Tempus AI (TEM) announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology Annual Meeting. Tempus has been building novel…
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Mul...
Tempus AI Transcript: Investor Day 2026
A sustainable, AI-driven healthcare platform now spans 5,000+ U.S. institutions, offering comprehensive diagnostics, data, and applications. Diagnostics growth is fueled by new FDA approvals and algorithmic insights, while the data business is expanding rapidly with major pharma partnerships and advanced AI models.
Tempus AI Slides: FY 2026
Tempus AI has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 29, 2026.
Tempus AI receives FDA approval for tumor-only xT CDx
Tempus AI (TEM) announced that the U.S. Food and Drug Administration has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Temp...
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA)...
Tempus AI announces expansion of indications to Next platform
Tempus AI (TEM) announced an expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology Annual Meeting. Next establishes a new category…